title: BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
authors.affiliation: Department of Urology, RWTH Aachen, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Jakse
authors.forename: R
authors.initials: R
authors.lastname: Hall
authors.forename: A
authors.initials: A
authors.lastname: Bono
authors.forename: W
authors.initials: W
authors.lastname: Höltl
authors.forename: P
authors.initials: P
authors.lastname: Carpentier
authors.forename: M
authors.initials: M
authors.lastname: de Pauw
authors.forename: R
authors.initials: R
authors.lastname: Sylvester
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D002985:Clinical Protocols; D003556:Cystitis / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D014374:Tuberculin Test; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine